Cartesian Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

Gaithersburg, MD 4,160 followers

Pioneering RNA cell therapy for autoimmune disease

About us

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

Gaithersburg, MD

Type

Public Company

Founded

2016

Specialties

Immunotherapy, Oncology, Molecular Biology, Immunology, Autoimmune Diseases, Myasthenia Gravis, ARDS, Cell Therapy, Lung disease, NETs, Cardiovascular Disease, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, and CAR-T

Locations

Employees at Cartesian Therapeutics

Updates

Later this year, Cartesian’s CSO Christopher M. Jewell will present at the Cell Therapy Autoimmune Summit. Chris will discuss the unique challenges of cell therapies in the #autoimmune space, and how Cartesian is addressing them through the development of differentiated mRNA therapies. More details here: https://bit.ly/46HNsEy

Program Director at Hanson Wade | 6th TIL Therapies Summit 2024 | 2nd Cell Therapies for Autoimmune Disease Summit 2024 | 10th Innate Killer Summit 2025
3w
“It’s amazing to have a group of experts and different stakeholders come together at the 2nd Cell Therapy for Autoimmune Disease Summit to focus on this topic. It’s a great networking opportunity to connect with people to understand where the field is and what the challenges are’’ I recently had an exciting conversation with Christopher M. Jewell, the Chief Scientific Officer at Cartesian Therapeutics. We dove into the explosive growth of the field, its bright future, the challenges on the horizon, and the innovative work being driven by Cartesian. The full conversation is available to watch here: https://ter.li/0arlu6
Join us at next week’s Cell & Gene Live event discussing modernizing CAR-T manufacturing, where Cartesian’s Emily English will speak about the challenges, opportunities, and future of CAR-T cell therapies. Register here: https://bit.ly/4cn8Lwc
Happening next week: Cartesian team members Christopher M. Jewell and Emily English are presenting at the 4th mRNA-Based Therapeutics Summit on understanding mRNA cell therapy and how Cartesian is expanding the reach to #autoimmune diseases. We hope to see you there!
Thank you to everyone who attended our educational session at #AANSC on the benefits of mRNA CAR-T therapy and highlights from our recently completed Phase 2b trial of Descartes-08 in #myastheniagravis. Learn more about our science: https://bit.ly/3Qr2LdY

Join now to see what you are missing

Join now

Cartesian Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

Gaithersburg, MD 4,160 followers

Pioneering RNA cell therapy for autoimmune disease

About us

Locations

Employees at Cartesian Therapeutics

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding